<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953131</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0659</org_study_id>
    <secondary_id>NCI-2019-00214</secondary_id>
    <secondary_id>2018-0659</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03953131</nct_id>
  </id_info>
  <brief_title>Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas</brief_title>
  <official_title>A Pilot Study of 68Ga-Dotatate PET CT for Radiation Treatment Response Assessment in Meningiomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography
      (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas.
      Giving Gallium Ga 68-DOTATATE before PET/CT scan may work better in predicting tumor growth
      in patients with meningiomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the ability of imaging with gallium Ga 68-DOTATATE (68Ga-DOTATATE) positron
      emission tomography/computed tomography (PET/CT).

      II. To assess a metabolic response to radiation therapy in meningiomas as measured by a
      reduction in the tumor to background ratio of the maximum standardized uptake values (SUV) of
      the tumor compared to background brain parenchyma.

      OUTLINE:

      Patients receive gallium Ga 68-DOTATATE intravenously (IV) over a few minutes and, after 60
      minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation
      therapy and 6 weeks after completion of radiation treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging with Gallium Ga 68-DOTATATE</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Lesions will be defined based on areas of T1 post contrast enhancement as assessed by magnetic resonance imaging (MRI). The largest bidimension measurements of the lesion on post-contrast T1 weighted magnetic resonance (MR) imaging will be recorded. Regions of interest (ROI) analysis of these regions of abnormal enhancement will be used to assess the max standard uptake values (SUV) of the lesion (tumor) as well as adjacent normal appearing brain parenchyma (background). These calculations will be repeated on the post-treatment scan as well as calculations for tumor to background (T/B) ratios.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic response to radiation therapy</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be measured by a reduction in the tumor to background ratio of the maximum SUV of the tumor compared to background brain parenchyma.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (gallium Ga 68-DOTATATE PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gallium Ga 68-DOTATATE IV over a few minutes and, after 60 minutes, undergo a PET/CT scan over 5-10 minutes 14 days before starting scheduled radiation therapy and 6 weeks after completion of radiation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (gallium Ga 68-DOTATATE PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>computerized tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68-DOTATATE</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (gallium Ga 68-DOTATATE PET/CT)</arm_group_label>
    <other_name>(68)Ga-DOTA-TATE</other_name>
    <other_name>68Ga-DOTATATE</other_name>
    <other_name>Gallium-68 DOTA-DPhe1, Tyr3-octreotate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (gallium Ga 68-DOTATATE PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any meningioma with at least 10 mm measurable residual disease

          -  Planned radiation therapy for meningioma

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Neurofibromatosis type 1 or 2

          -  Pregnant

          -  Contraindication to magnetic resonance (MR) imaging

          -  Body weight greater than 400 pounds (lbs) (181.4kg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason M Johnson</last_name>
    <phone>713-792-8443</phone>
    <email>jjohnson12@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M. Johnson</last_name>
      <phone>713-792-8443</phone>
    </contact>
    <investigator>
      <last_name>Jason M. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

